A forthcoming conference promises insights into the latest innovations in improving solubility of drug compounds, according to its organisers.
The Enhanced Solubility and Bioavailability conference will cover accurately measuring and predicting solubility, effectively overcoming poor solubility of new compounds, and evaluating formulation strategies for efficient early-phase development.
The organisers say poor solubility turns the development of new drugs into a major challenge. Today, poorly soluble compounds represent about 60% of compounds and marketed drugs – and the number of poorly soluble compounds is actually increasing.
Many companies are working on new techniques to measure, predict and improve solubility. Selecting and applying the optimal challenge is a major hurdle but also offers the main success factor and competitive advantage.
The organisers say the conference will provide excellent scientific insights with industrial and wider relevance. Delegates can learn from global best practice by:
* Exploring different solubility methods to understand each technique sbenefits and pitfalls.
* Discussing how to measure solubility and bioavailability to predict the feasibility of compound candidates.
* Assessing nanocrystal technology for improving dissolution rates and bioavailability.
* Gaining an insight into cyclodextrines and understanding their impact on solubility enhancement.
* Hearing about in silico technologies to predict solubility and drug absorption.
Information will be available from companies including Novo Nordisk, Bristol-Myers Squibb, Abbott, Basilea, Pfizer, Merck, B. Braun Melsungen, UCB, Boehringer Ingelheim, Hoffmann-La Roche, Amgen and Johnson & Johnson, as well as universities Liverpool John Moores University (UK), Université d Auvergne (France) and the Free University of Berlin (Germany).
The meeting is to be held on 18–20 February 2008 at Le Méridien Parkhotel Frankfurt, Frankfurt, Germany.